Omilancor

New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients Omilancor and NIM-1324 reduced disease severity, pathology and recurrence in models of IBD and bacterial infection co-occurrence Results highlight the power of the TITAN-X precision medicine platform and its use of advanced AI to unravel the complexity of the immune system and to develop innovative medicines BLACKSBURG, Va.--(BUSINESS WIRE)-- #ACG2026 --NImmune Biopharma (“NImmune”), a private precision inflammation and immunology (“I&I”) biopharmaceutical company, announced results presented at the American College of Gastroenterology 2026 Annual Scientific Meeting (“ACG 2026”) supporting the efficacy, safety, and the broader therapeutic potential of LANCL2-targeting medicines in difficult-to-treat inflammatory bowel disease (“IBD”). The two studies provide complementary evidence supporting NImmune’s LANCL2 therapeutic portfolio across challenging patient populations and a wide range of disease indications. Omilancor and NIM-1324 are oral, once-daily innovative LANCL2 medicines that target a novel mechanism of action and are being developed for the treatment of inflammatory and autoimmune diseases. In the presentation, “LANCL2 Activation Ameliorates Immune and Metabolic Transcriptional Patterns Associated with Biologic Refractoriness in Ulcerative Colitis and Crohn’s Disease,” investigators evaluated a 78-gene signature associated with inflammation and nonresponse to multiple classes of biologic therapies. After 12 weeks of treatment, omilancor reduced the biologic-refractory score by more than 55% from baseline and reduced expression of genes associated with biologic refractoriness by greater than two-fold on average. Patients with prior biologic use also experienced clinical, symptomatic and endoscopic remission at rates similar to the overall and biologic-naive populations. These findings provide new clinical evidence that LANCL2 activation may address inflammatory, metabolic and fibrotic processes associated with treatment refractoriness in IBD patients and support the therapeutic potential of innovative LANCL2 medicines for severe patients who have failed or lost response to biologic therapies. The second presentation, “NIM-1324 Activates LANCL2 to Reduce Recurrence and Disease Severity in IBD and Clostridioides difficile Infection Co-occurrence Models,” evaluated omilancor and NIM-1324. In these preclinical IBD and CDI co-occurrence models, both omilancor and NIM-1324 reduced weight loss and disease activity, decreased gut pathology, improved survival and reduced recurrent bacterial burden. Oral treatment with LANCL2 medicines also maintained regulatory immune responses and supported greater gut microbiome diversity, including increased abundance of beneficial commensal bacteria associated with protection from infection. “These novel findings presented at ACG26 further support our strong conviction that LANCL2 is the better target for a wide range of inflammatory and autoimmune diseases and highlight the huge therapeutic potential of first-in-class oral, once-daily LANCL2 medicines for addressing the unmet clinical needs of difficult-to-treat IBD,” said Dr. Josep Bassaganya-Riera, Founder, Executive Chairman, President and Chief Executive Officer of NImmune Biopharma. “The use of advanced AI for the development of LANCL2 medicines also helped accelerate the discovery of novel targets such as LANCL2 and streamlined the path from drug discovery to clinical testing by 3 to 7 years. These studies demonstrate that LANCL2 medicines can alter the underlying biology associated with refractoriness to current IBD therapies and decrease the risk of infection which is one of the most typical adverse side effects from current IBD medications.” Both omilancor and NIM-1324 are being developed using NImmune’s TITAN-X platform, combining advanced AI, computational modeling, bioinformatics and mechanistic research to identify disease pathways and guide development. By integrating these computational capabilities with biomedical and translational research, TITAN-X is designed to accelerate the development of differentiated precision immunoregulatory therapeutics. The two clinical-stage therapeutic assets illustrate how NImmune is applying the A.I. platform across its inflammation and immunology (I&I) drug development programs. About NImmune Biopharma NImmune is a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that leverages a proprietary advanced A.I. platform to rapidly and capital efficiently develop novel best-in-class biomarker-driven immunoregulatory therapeutics for metabolic, inflammatory and autoimmune diseases. Underpinned by the TITAN-X computational platform that utilizes advanced A.I., computational modeling, and bioinformatics and biomedical research capabilities to pioneer innovation in the development and commercialization of novel best-in-class I&I therapies, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates to New Drug Application (NDA) filing and commercialization. Additional information: . About NIMML The NIMML Institute is a 501(c)(3) non‑profit foundation dedicated to combining advanced artificial intelligence–driven computational modeling with translational research and clinical testing to accelerate development of the next wave of precision medicines for inflammatory and autoimmune diseases. The Institute applies its TITAN‑X™ advanced A.I.‑powered platform to large‑scale, transdisciplinary projects aimed at solving important public health challenges by unraveling the complexity of the immune system. The NIMML Institute is headquartered in Blacksburg, Virginia. For more information, please visit . Contacts Dr. Josep Bassaganya-Riera Founder, President & CEO NImmune Biopharma, Inc 540-818-2844 jbassaganya@nimmunebio.com

Study provides a comprehensive, time-course systems-wide analysis of radiation-induced gene expression changes in the gut during GI acute radiation syndrome Identifies novel therapeutic targets to address unmet clinical needs in gastrointestinal acute radiation syndrome Studies leveraged the A.I.-powered TITAN-X Precision Medicine Platform, which has played a crucial role in the development of oral therapeutics for inflammatory and autoimmune diseases BLACKSBURG, Va.--(BUSINESS WIRE)--The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious, inflammatory and autoimmune diseases, today announced the publication of new peer-reviewed article in the International Journal of Radiation Biology titled, “ Immunometabolic Mechanisms of Ionizing Radiation in a Mouse Model of Gastrointestinal Acute Radiation Syndrome .” The study is a comprehensive, system-wide transcriptional analysis providing new insights into the response mechanisms underlying ionizing radiation-induced intestinal damage and subsequent mortality, along with identification of novel immunometabolic mechanisms with strong potential for therapeutic development in gastrointestinal acute radiation syndrome (“GI-ARS”). The publication of this research, which is funded by the Defense Threat Reduction Agency (“DTRA”) follows the presentation of the associated abstract, “Colonic immunometabolic host response mechanisms to ionizing radiation in a mouse model of acute radiation syndrome” by NIMML at the IMMUNOLOGY2026 conference. GI-ARS is a severe and often life-threatening consequence of high-dose ionizing radiation (“IR”). Exposure to high doses of IR can cause extensive damage to the gastrointestinal tract by disrupting the rapid renewal of the intestinal epithelium and endothelial barrier functions, leading to increased vascular permeability, translocation of harmful gut microbes, triggering systemic inflammation, sepsis, organ failure and other life-threatening complications. As the presence of radioactive materials, nuclear facilities and geopolitical instability increases, the need for safe and effective medical countermeasures has become increasingly urgent. Although supportive interventions exist, there remains a significant unmet clinical need for safe and effective therapies that directly target radiation-induced gastrointestinal injury. “This research provides important novel insights into how lethal ionizing radiation disrupts gene expression in the gastrointestinal tract over time,” said Dr. Josep Bassaganya-Riera, corresponding author of the study and NIMML’s President and Founding Director. “By identifying distinct immunometabolic patterns associated with disease progression and mortality, this work advances our understanding of GI-ARS and helps establish a stronger scientific foundation for the development of targeted medical countermeasures for use in nuclear emergencies.” In the study, researchers conducted a global transcriptomic time-course analysis in a mouse model exposed to sublethal and lethal total body irradiation. Analysis of colonic gene expression across multiple time points identified 23 distinct temporal patterns of differential gene expression, including three clusters associated with mortality. These clusters were enriched in pathways related to innate immunity, adaptive immunity and sterol metabolism. The findings showed that lethal radiation exposure was associated with a distinct time-dependent response, including early and late inflammatory activity, a late increase in adaptive immune gene expression and downregulation of sterol metabolism pathways. Together, these patterns provide additional insight into the molecular features associated with GI-ARS progression and mortality. The study also demonstrated dose-dependent effects, with milder responses at lower radiation doses and worsening gastrointestinal injury and mortality at the highest dose. These findings further support the model’s utility for studying GI-ARS and identifying potential for therapeutic development. “I am excited that we are making meaningful progress toward the treatment of acute GI effects associated with IR exposure, which continues to present an urgent and unmet medical need,” said Heather Meeks, Counter-WMD Technologies Senior Scientist. “Leveraging the capabilities of the NIMML TechBioHub in Blacksburg, including the capabilities of the A.I.-powered TITAN-X Precision Medicine Platform, the NIMML Institute, BioTherapeutics, and NImmune Biopharma, we are pushing the boundaries of scientific discovery. I am confident that our improved understanding of the effects of acute radiation exposure will lead to the discovery of more effective medical countermeasures.” This breakthrough research was supported by NIMML’s broader expertise and longstanding track record in advanced computational modeling and systems immunology, including the use of its A.I.-powered TITAN-X Precision Medicine Platform. TITAN-X is designed to integrate large-scale datasets with bioinformatics, clinical insights and advanced computational modeling to study immunity as a dynamic, systems-level network interconnected with metabolic processes. By uncovering predictive transcriptional signatures and linking immune and metabolic responses over time, TITAN-X helps inform the identification of novel therapeutic targets and supports the development of targeted, biomarker-driven countermeasures for GI-ARS. This comprehensive transcriptional analysis provides important new insight into the mechanisms underlying radiation-induced intestinal damage and mortality and highlights novel immunometabolic pathways that may help guide the development of much-needed therapeutic approaches for GI-ARS, an area of significant unmet medical need. About the TITAN-X Platform The TITAN-X Precision Medicine Platform combines A.I. methodologies, bioinformatics, and advanced computational modeling to accelerate the development of precision medicines to address the unmet clinical needs of patients with autoimmune diseases. Building upon NIMML’s expertise in engineering large-scale computational models to study immunity as a massively and dynamically interacting system, the TITAN-X Platform integrates each step from new target discovery to enabling biomarker-driven precision clinical drug development. Following bioinformatic analysis of differentially expressed genes from patient biopsy specimens, the TITAN-X Platform can identify transcriptional predictive signatures by using its advanced A.I. algorithms. By analyzing gene expression patterns and integrating clinical data, the TITAN-X Platform can identify responder patterns, facilitating precision medicine approaches for drug development. This ensures that patients receive therapies that are most likely to benefit them according to their unique genetic signatures and clinical pro and that are tailored to maximize efficacy, safety, tolerability and minimize adverse side effects. The TITAN-X Platform has shaped the clinical development of omilancor, NX-13 (acquired by Abbvie in March 2024 and now called ABBV-113), NIM-1324 and multiple additional novel MoA targets and drug candidates in preclinical development for I&I indications. About NIMML The NIMML Institute is a 501 (c) (3) non-profit foundation focused on applying transdisciplinary, team-science approaches to precision medicine. The NIMML Institute applies its TITAN-X advanced A.I.-powered platform to large-scale transdisciplinary projects aimed at solving important public health problems through precision medicine. NIMML combines the expertise of immunologists, computational biologists, toxicologists, computational modelers, translational and clinical researchers, and molecular biologists to translate novel scientific discoveries into medicines for human diseases. The Institute is headquartered in Blacksburg, VA. For more information, please visit . About NImmune Biopharma NImmune is a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that leverages a proprietary A.I. platform to rapidly and capital efficiently develop novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases. Underpinned by the TITAN-X computational platform that utilizes advanced A.I., advanced computational modeling, and bioinformatics and biomedical research capabilities to pioneer innovation in the development and commercialization of novel best-in-class I&I therapies, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates to New Drug Application (NDA) filing and commercialization. Additional information: . Contacts Media Contact: Alex Jeffrey/Jonathan Warren Gasthalter & Co. nimmune@gasthalter.com 212.257.4170